The primary disease process in myelofibrosis with myeloid metaplasia (MMM) is clonal
myeloproliferation with varying degrees of phenotypic differentiation. This is …

Among 2333 consecutive patients with myelofibrosis with myeloid metaplasia (MMM) seen
at our institution, 91 fulfilled the World Health Organization (WHO) criteria for leukemic …

Essential thrombocythaemia was first described over 70 years ago. This condition is
dominated by thrombotic and haemorrhagic complications and, in the long‐term, by risk of …

A prospective pilot study was performed to evaluate the effect of reduced‐intensity
conditioning with busulphan (10 mg/kg), fludarabine (180 mg/qm) and anti‐thymocyte …

Significant progress in our understanding of the molecular pathogenesis of essential
thrombocythemia (ET) and the other Philadelphia (Ph) chromosome–negative …

The conventional treatment of myelofibrosis involves a wait‐and‐see approach for
asymptomatic patients, oral chemotherapy for the hyperproliferative forms of the disease …

The association between a prothrombin mutation and the risk of thrombosis was analyzed in
214 patients with polycythemia vera or essential thrombocythemia. The rate for venous …

Myelofibrosis with myeloid metaplasia (MMM) is an infrequent disease usually affecting
elderly people. Due to the lack of a specific marker for MMM, efforts are being made to refine …

Agnogenic myeloid metaplasia (AMM) is a clonal stem cell disorder that leads to ineffective
hematopoiesis, bone marrow fibrosis, and extramedullary hematopoiesis. The molecular …

The aim of this study was to investigate the prognostic relevance of angiogenesis expressed
as bone marrow microvessel density (MVD) in 40 patients with essential thrombocythemia …